Indian Patent Office
-
{
- All
- News
-
ISB, Deloitte, Nasscom Develop Index for Global In-house Centres in India
- Thursday December 7, 2023
- Author: NDTV Profit Desk
Indian School of Business (ISB) and Deloitte Consulting, in association with IT industry body Nasscom, have developed a maturity index for global in-house centres (GICs) in India to help them benchmark their performance relative to industry peers.
-
www.ndtvprofit.com
-
Government To Communicate With Design Applicants Via Email
- Monday September 12, 2016
- Press Trust of India
The Indian Patent Office has decided that all official communications for registration of designs will be communicated through email or the applicant's digital address.
-
www.ndtvprofit.com
-
Top American Business Group Seeks Clarity In India's Compulsory License Policy
- Friday April 15, 2016
- India News | Press Trust of India
Top American business advocacy group USIBC has sought transparency, consistency and clarity in the compulsory license policy of the Indian government in a bid to attract investments that are "imperative" for innovation.
-
www.ndtv.com
-
ISB, Deloitte, Nasscom Develop Index for Global In-house Centres in India
- Sunday August 10, 2014
Indian School of Business (ISB) and Deloitte Consulting, in association with IT industry body Nasscom, have developed a maturity index for global in-house centres (GICs) in India to help them benchmark their performance relative to industry peers.
-
www.ndtvprofit.com
-
Pfizer to appeal India decision to revoke cancer drug patent
- Friday October 5, 2012
Pfizer Ltd, the India unit of U.S. drugmaker Pfizer Inc, will challenge the country's patent office for revoking a patent for its cancer drug Sutent. The company, which will appeal before the Intellectual Property Appellate Board, said on Friday the Indian Patent Office's decision raised concerns over India's commitment to protect intellectual prop...
-
www.ndtvprofit.com
-
Cancer ruling opens door for cheaper drugs in India
- Wednesday June 6, 2012
On Monday, the Indian Patent Office effectively ended Bayer's monopoly for its Nexavar drug and issued its first-ever compulsory license allowing local generic maker Natco Pharma to make and sell the drug cheaply in India.
-
www.ndtvprofit.com
-
ISB, Deloitte, Nasscom Develop Index for Global In-house Centres in India
- Thursday December 7, 2023
- Author: NDTV Profit Desk
Indian School of Business (ISB) and Deloitte Consulting, in association with IT industry body Nasscom, have developed a maturity index for global in-house centres (GICs) in India to help them benchmark their performance relative to industry peers.
-
www.ndtvprofit.com
-
Government To Communicate With Design Applicants Via Email
- Monday September 12, 2016
- Press Trust of India
The Indian Patent Office has decided that all official communications for registration of designs will be communicated through email or the applicant's digital address.
-
www.ndtvprofit.com
-
Top American Business Group Seeks Clarity In India's Compulsory License Policy
- Friday April 15, 2016
- India News | Press Trust of India
Top American business advocacy group USIBC has sought transparency, consistency and clarity in the compulsory license policy of the Indian government in a bid to attract investments that are "imperative" for innovation.
-
www.ndtv.com
-
ISB, Deloitte, Nasscom Develop Index for Global In-house Centres in India
- Sunday August 10, 2014
Indian School of Business (ISB) and Deloitte Consulting, in association with IT industry body Nasscom, have developed a maturity index for global in-house centres (GICs) in India to help them benchmark their performance relative to industry peers.
-
www.ndtvprofit.com
-
Pfizer to appeal India decision to revoke cancer drug patent
- Friday October 5, 2012
Pfizer Ltd, the India unit of U.S. drugmaker Pfizer Inc, will challenge the country's patent office for revoking a patent for its cancer drug Sutent. The company, which will appeal before the Intellectual Property Appellate Board, said on Friday the Indian Patent Office's decision raised concerns over India's commitment to protect intellectual prop...
-
www.ndtvprofit.com
-
Cancer ruling opens door for cheaper drugs in India
- Wednesday June 6, 2012
On Monday, the Indian Patent Office effectively ended Bayer's monopoly for its Nexavar drug and issued its first-ever compulsory license allowing local generic maker Natco Pharma to make and sell the drug cheaply in India.
-
www.ndtvprofit.com